Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
24. März 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
16. März 2020 16:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock
11. März 2020 20:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Proposed Public Offering of Common Stock
11. März 2020 16:15 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome
11. März 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007
06. März 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
26. Februar 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March
19. Februar 2020 08:02 ET
|
Seelos Therapeutics, Inc.
Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) --...
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
13. Februar 2020 16:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
10. Februar 2020 20:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...